Shares of Moderna MRNA were up 15.8% on Jan. 21, after the company and its partner Merck MRK announced positive median ...
Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.
Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or ...
Moderna (MRNA) stock is in focus as the mRNA-based cancer drug with Merck's (MRK) Keytruda cut melanoma recurrence/death risk ...
By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...
Zacks.com on MSN
Is BMY's Deep Pipeline the Key to Its Next Growth Phase?
Bristol Myers Squibb BMY highlighted the potential of its deep and promising pipeline at the 44th Annual J.P. Morgan Healthcare Conference, held earlier this month. Key pipeline candidates in BMY’s ...
GSK agrees to buy RAPT Therapeutics for $2.2B, adding ozureprubart to its pipeline and strengthening its respiratory and ...
Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.
USA-based mRNA vaccines company Moderna’s shares were flat in pre-market activity, as the company announced awaited new ...
The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...
The latest investor updates on stocks that are trending on Thursday.
Regeneron Pharmaceuticals, Inc. nears a key earnings report after a strong JPM Healthcare update. Click here to find out why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results